The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
Winer
Eric
E
Department of Medicine, Harvard Medical School, Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D017698:Postmenopause; D017697:Premenopause; D013629:Tamoxifen / Q000627:therapeutic use*; D013997:Time Factors
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen